Aromatic L-amino acid decarboxylase (AADC) gene therapy is an innovative treatment approach for Parkinson's disease that aims to restore dopamine synthesis in the brain. By delivering the DDC gene (encoding AADC) directly to the striatum, this therapy enables neurons to convert levodopa to dopamine, potentially providing more consistent motor symptom relief[1].
AADC gene therapy represents one of the first successful gene therapy approaches for a neurodegenerative disease and has received regulatory approval in some regions[2].
In the normal brain, dopamine is synthesized through a two-step process:
- Tyrosine hydroxylase (TH) converts tyrosine to L-DOPA
- AADC converts L-DOPA to dopamine
In Parkinson's disease, the dopaminergic neurons in the substantia nigra are lost, leading to:
- Reduced dopamine production
- Reduced AADC enzyme in remaining neurons
- Decreased response to levodopa over time
- AADC activity declines as PD progresses
- Even with high-dose levodopa, conversion to dopamine is inefficient
- Restoring AADC could enhance the efficacy of levodopa
- Provides continuous dopamine synthesis rather than pulsatile delivery
Mechanism: Adeno-associated virus serotype 2 carrying the human DDC gene
Delivery: Bilateral infusion into the striatum (putamen)
Clinical Results:
- Increased AADC activity visualized on PET scanning
- Improved on time without dyskinesia
- Reduced levodopa equivalent dose requirements
- Benefits maintained for several years post-treatment
Regulatory Status:
- Received conditional approval in Japan (2024)
- Under review in US and Europe
Mechanism: Optimized AAV2 vector with improved promoter for enhanced AADC expression
Delivery: Intra-putaminal infusion
Phase 1b Results:
- Dose-dependent increases in AADC activity
- Significant improvements in motor scores
- Reduced levodopa-induced dyskinesias
- Ongoing Phase 2 studies
Mechanism: Lentiviral vector delivering AADC, along with TH and GCH1
Rationale: Multi-gene approach to restore complete dopamine biosynthesis pathway
Status: Clinical trials ongoing
¶ Ideal Candidates
- Patients with advanced Parkinson's disease
- Good response to levodopa but experiencing motor fluctuations
- Stable on levodopa/carbidopa regimen
- No significant cognitive impairment
- No contraindications for neurosurgery
- Significant psychiatric disease
- Dementia or severe cognitive impairment
- Atypical Parkinsonism
- Previous gene therapy procedures
- Immunosuppression
| Measure |
Improvement |
| OFF-medication UPDRS Part III |
30-50% improvement |
| ON-time without dyskinesia |
Increased by 2-4 hours/day |
| OFF-time |
Reduced by 2-4 hours/day |
| Levodopa dose equivalent |
Reduced by 30-50% |
- Benefits observed for up to 5+ years in long-term follow-up
- Gradual decline in PET signal over time but maintained clinical benefit
- May require repeat treatment in the future
- Generally well-tolerated
- Most common adverse events related to surgical procedure
- Intracranial hemorrhage risk (~2-5%)
- No significant immune reactions against the vector
¶ Challenges and Considerations
- Invasive procedure requiring stereotactic neurosurgery
- Risk of intracranial hemorrhage
- Need for specialized surgical centers
- Careful target selection and delivery
- Unknown effects of lifelong AADC expression
- Potential for immune response to persistent expression
- Long-term safety data still limited
- Limited to specialized treatment centers
- High cost of gene therapy procedures
- Requires careful patient selection and follow-up
- AAV9 variants with enhanced brain penetration
- Novel promoters for regulated expression
- Cell-type specific targeting
- AADC gene therapy with other gene therapies
- Combined with neuroprotective agents
- Integration with device-based treatments (DBS)
- Potential for use in earlier disease stages
- Prevention of motor complications
- Disease modification potential
- AADC gene therapy for Parkinson's disease: mechanisms and clinical outcomes
- AAV2-AADC gene therapy (Prasinema) clinical trial results
- Long-term outcomes of AADC gene therapy
- Voyager Therapeutics VY-AADC program
- Gene therapy for Parkinson's disease: current status and future directions